Wegovy® will be the preferred GLP-1 medicine for obesity on the largest commercial template formularies for CVS Caremark, the largest Pharmacy Benefit Manager (PBM) in the US, effective July 1, 2025 Novo Nordisk is focused on new ways to drive access and affordability for Wegovy®, the...
Hence then, the article about novo nordisk announces that cvs caremark the country s largest pbm has decided wegovy will be the preferred glp 1 medicine covered for obesity on its template formularies was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Novo Nordisk announces that CVS Caremark®, the country's largest PBM, has decided Wegovy® will be the preferred GLP-1 medicine covered for obesity on its template formularies )
Also on site :
- Berkshire Hathaway to Acquire Taylor Morrison Home Corporation for $8.5 Billion
- 2026 ASCO .. Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC
- D3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in Untreated NSCLC